

Kevin J Anstrom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/694711/publications.pdf>

Version: 2024-02-01

67
papers

4,499
citations

126858

33
h-index

106281

65
g-index

69
all docs

69
docs citations

69
times ranked

6130
citing authors

#	ARTICLE	IF	CITATIONS
1	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
2	Palliative Care in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 331-341.	1.2	425
3	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
4	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	1.6	235
5	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	13.9	225
6	Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1044-1048.	2.5	209
7	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	3.8	187
8	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
9	Clinical Effectiveness of Coronary Stents in Elderly Persons. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1629-1641.	1.2	135
10	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	1.9	106
11	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. <i>American Heart Journal</i> , 2014, 167, 796-803.e1.	1.2	104
12	Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study. <i>JMIR Medical Informatics</i> , 2020, 8, e15182.	1.3	86
13	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	3.0	74
14	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 388-396.	5.2	69
15	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	0.4	68
16	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	1.9	65
17	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. <i>Circulation</i> , 2016, 133, 39-47.	1.6	58
18	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Tj ETQq0 0 0 rgBj/Overlook 10 Tf 50		

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	3.0	53
20	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 750.	3.0	50
21	Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001403.	1.4	47
22	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
23	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
24	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	2.1	45
25	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	1.6	45
26	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1841.	3.8	43
27	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 673-679.	1.6	41
28	Percutaneous Coronary Intervention and Drug-Eluting Stent Use Among Patients \geq 85 Years of Age in the United States. <i>Journal of the American College of Cardiology</i> , 2012, 59, 105-112.	1.2	40
29	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.4	40
30	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	38
31	Long-term survival estimates for imatinib versus interferon- γ plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004, 101, 2584-2592.	2.0	35
32	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	3.8	35
33	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 3243-3250.	1.0	35
34	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease. <i>Circulation</i> , 2016, 133, 1995-2007.	1.6	35
35	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 14-23.	2.5	32
36	A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime. <i>Biometrics</i> , 2010, 66, 512-522.	0.8	31

#	ARTICLE	IF	CITATIONS
37	Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial. <i>Circulation: Heart Failure</i> , 2015, 8, 221-228.	1.6	31
38	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. <i>Journal of the American College of Cardiology</i> , 2015, 65, 465-476.	1.2	30
39	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	1.9	30
40	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	1.9	30
41	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2014, 146, 1256-1262.	0.4	28
42	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	25
43	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	1.2	23
44	Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep Apnea. <i>Heart Rhythm</i> , 2019, 16, 91-97.	0.3	20
45	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2016, 1, 655.	3.0	19
46	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	19
47	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	3.0	18
48	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy â€” the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. <i>Respiratory Research</i> , 2020, 21, 68.	1.4	17
49	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16
50	Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare-linked National Cardiovascular Data Registry Cath PCI Registry (2005-2009). <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 43-49.	0.7	16
51	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16
52	Long-term Clinical Outcomes Following Coronary Stenting. <i>Archives of Internal Medicine</i> , 2008, 168, 1647.	4.3	14
53	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015, 4, e002061.	1.6	14
54	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 145-151.	2.1	14

#	ARTICLE	IF	CITATIONS
55	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2304-2313.	1.2	14
56	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018, 204, 202-204.	1.2	14
57	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. <i>American Heart Journal</i> , 2016, 177, 33-41.	1.2	13
58	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
59	Predictive ability of perioperative atrial fibrillation risk indices in cardiac surgery patients: a retrospective cohort study. <i>Canadian Journal of Anaesthesia</i> , 2018, 65, 786-796.	0.7	12
60	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	10
61	Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2014, 114, 716-722.	0.7	9
62	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	9
63	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	7
64	Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107616.	1.2	3
65	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , 2016, 5, e12.	0.6	3
66	Examination of the Treatment Selection Process in a Multicenter Observational Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 764-769.	0.9	0
67	Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1071.	3.8	0